IRIS PubliCatt

Ponziani, Francesca Romana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.850
NA - Nord America 3.645
AS - Asia 1.497
AF - Africa 29
SA - Sud America 21
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 12
Totale 9.068
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.604
DE - Germania 1.165
SE - Svezia 788
IT - Italia 674
CN - Cina 589
SG - Singapore 495
IE - Irlanda 288
UA - Ucraina 235
FR - Francia 182
ID - Indonesia 168
GB - Regno Unito 110
FI - Finlandia 105
RU - Federazione Russa 99
IN - India 86
TR - Turchia 56
BE - Belgio 42
PL - Polonia 34
CA - Canada 31
HK - Hong Kong 29
CZ - Repubblica Ceca 23
IR - Iran 22
CI - Costa d'Avorio 19
NL - Olanda 19
RO - Romania 14
CH - Svizzera 13
ES - Italia 13
BR - Brasile 12
JP - Giappone 12
AU - Australia 11
EU - Europa 9
AT - Austria 7
GR - Grecia 6
IL - Israele 6
IQ - Iraq 5
KR - Corea 5
LT - Lituania 5
TZ - Tanzania 5
MX - Messico 4
VN - Vietnam 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
CL - Cile 3
EC - Ecuador 3
HR - Croazia 3
HU - Ungheria 3
MK - Macedonia 3
NO - Norvegia 3
PA - Panama 3
PK - Pakistan 3
A1 - Anonimo 2
DK - Danimarca 2
EE - Estonia 2
EG - Egitto 2
MD - Moldavia 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
SA - Arabia Saudita 2
SC - Seychelles 2
SI - Slovenia 2
AL - Albania 1
AR - Argentina 1
BD - Bangladesh 1
BG - Bulgaria 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
CY - Cipro 1
GL - Groenlandia 1
IM - Isola di Man 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
ME - Montenegro 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 9.068
Salva come PNG Salva come JPEG
Città #
Chandler 848
Singapore 398
Ashburn 303
Dublin 286
Jakarta 165
New York 159
San Mateo 150
Jacksonville 139
Cattolica 125
Ann Arbor 115
Rome 109
Wilmington 97
Milan 96
Boston 94
Nanjing 87
Marseille 85
Moscow 79
Princeton 72
Boardman 59
Nürnberg 57
Beijing 56
Redwood City 53
Helsinki 50
Chicago 49
Izmir 48
Zhengzhou 45
Munich 44
Dearborn 43
Lawrence 42
Brussels 41
Woodbridge 41
Los Angeles 38
Bremen 36
Houston 35
Fairfield 34
Nanchang 32
Seattle 31
Hangzhou 26
Augusta 25
Pune 25
Hong Kong 24
Shenyang 24
Kraków 23
Guangzhou 22
Norwalk 22
Changsha 21
Hebei 20
Lancaster 20
Abidjan 19
Tianjin 19
Jiaxing 18
Mountain View 18
University Park 18
Paris 17
Frankfurt am Main 16
Brno 15
Kunming 15
Shanghai 15
Leawood 14
Toronto 14
London 12
Redmond 12
Ottawa 11
San Francisco 11
Andover 10
Cambridge 10
Warsaw 10
Arezzo 9
Jinan 9
Esslingen am Neckar 8
Fremont 8
Kish 8
Falkenstein 7
Lappeenranta 7
San Diego 7
Santa Clara 7
Atlanta 6
Las Vegas 6
Ningbo 6
Tappahannock 6
Vienna 6
Zurich 6
Berlin 5
Brdo 5
Edinburgh 5
Hounslow 5
Quanzhou 5
Washington 5
Aachen 4
Athens 4
Bern 4
Boydton 4
Castel di Sangro 4
Civitavecchia 4
Clearwater 4
Cluj-Napoca 4
Düsseldorf 4
Falls Church 4
Hefei 4
Melzo 4
Totale 4.951
Salva come PNG Salva come JPEG
Nome #
From small nodule to overt HCC: a multistep process of carcinogenesis as seen during surveillance 280
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment 278
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 149
HepPar1-Positive Circulating Microparticles Are Increased in Subjects with Hepatocellular Carcinoma and Predict Early Recurrence after Liver Resection 147
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound 145
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 135
Biomarkers of low-grade inflammation in primary varicose veins of the lower limbs 135
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development 132
Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis 127
Early prediction of response to Sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound 125
New modalities of ultrasound-based intima-media thickness, arterial stiffness and non-coronary vascular calcifications detection to assess cardiovascular risk 118
Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study 116
Diagnosis of bowel diseases: the role of imaging and ultrasonography 113
Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota 109
Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit 107
Diagnosis and treatment of small intestinal bacterial overgrowth 107
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 105
Gut microbiota and metabolic syndrome 96
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 94
Physiology and pathophysiology of liver lipid metabolism 93
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib 93
Liver transplantation in patients with alcoholic liver disease: A retrospective study 93
Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation 92
The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma 91
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 90
Use and indications of cholestyramine and bile acid sequestrants 89
Use and indications of cholestyramine and bile acid sequestrants 88
Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit 88
Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis. 85
Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients 85
HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 83
Anticoagulants in cirrhotic patients: controversies and certainties in PVT management 82
HEPATOCATT STUDY GROUP. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging. 79
Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment 79
Intestinal barrier in human health and disease 79
Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients? 77
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation 77
What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective 75
Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection 75
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C 73
Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms 73
Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease 73
Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban 72
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers 71
Radial Artery as a Coronary Artery Bypass Conduit: 20-Year Results 71
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. 71
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma 70
Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia 70
Morphological and functional consequences of transradial coronary angiography on the radial artery: Implications for its use as a bypass conduit 65
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib 64
Interventional oncology treatment for unresecable early stage HCC in patient with high risk for intraprocedural bleeding: is a single step combined therapy safe and feasible? 63
A novel ultrasound-based vascular calcification score (CALCS) to detect subclinical atherosclerosis 63
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports 63
Management of hepatitis C virus infection recurrence after liver transplantation: an overview 61
Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience 61
Effect of liver transplantation on intestinal permeability and correlation with infection episodes 61
Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study 59
Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (< 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging 58
Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation 57
Project for interventional Oncology LArge-database in liveR Hepatocellular carcinoma - Preliminary CT-based radiomic analysis (POLAR Liver 1.1) 57
Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up. 56
Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 56
Diagnostic and prognostic role of circulating microparticles in hepatocellular carcinoma. 55
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C 55
Regorafenib: a promising treatment for hepatocellular carcinoma 55
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 54
Treatment of early stage chronic hepatitis C virus infection 54
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 54
The new era of hepatitis C treatment: still the tip of the iceberg? 53
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 53
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis 53
Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients 53
Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project 53
Diet-Induced Alterations in Gut Microbiota Composition and Function 53
How to modulate gut microbiota: diet, pre-probiotics or antibiotics? 52
Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate 52
Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study 52
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients 49
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation 49
Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) 48
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study 47
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma 47
Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation 46
Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors 45
Advances in pharmacotherapeutics for hepatocellular carcinoma 45
Durvalumab: an investigational agent for unresectable hepatocellular carcinoma 45
Viral cirrhosis: an overview of haemostatic alterations and clinical consequences 44
Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report 44
Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma 44
Personalized Therapy in a Multidisciplinary Team Improves Survival in Patient with HCC: The Hepatocatt Experience 43
Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications 43
Folate in gastrointestinal health and disease 42
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 42
Bariatric surgery and liver disease: General considerations and role of the gut–liver axis 42
MetaLiverCat: the NAFLD/NASH multidisciplinary board at Fondazione Policlinico Gemelli IRCCS 41
Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation 41
Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection 41
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 40
Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis 40
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 40
Totale 7.608
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.323
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.323
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020510 0 0 0 0 0 76 103 22 81 65 112 51
2020/2021676 62 54 10 57 70 34 60 10 84 62 149 24
2021/2022957 75 51 17 65 64 32 14 181 38 62 183 175
2022/20232.532 306 288 179 358 145 332 140 245 294 53 108 84
2023/20241.636 90 411 69 84 73 249 113 34 25 84 159 245
2024/2025977 92 87 306 89 283 120 0 0 0 0 0 0
Totale 9.291